Physician profile
Jay Mark Barnett
NPI 1396724779
$13,294.11
in general payments reported to CMS, 2019-2025
35 companies · $2,501 in 2025
The $2,501 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $862 · 2021: $1,667 · 2022: $1,678 · 2023: $2,324 · 2024: $2,530 · 2025: $2,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,196 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,195.54 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,213.59 | 2019-2025 | |
| Abbvie INC. | $2,135.48 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,549.71 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $921.34 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $832.37 | 2019-2025 | Bimzelx |
| Dermavant Sciences, INC. | $782.78 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $571.00 | 2019-2025 | Ilumya, Blu-U |
| Genzyme Corporation | $516.25 | 2019-2025 | |
| Pfizer INC. | $488.95 | 2019-2025 | |
| Amgen INC. | $273.53 | 2020-2025 | Otezla, Otezla |
| Strata Skin Sciences, INC. | $252.85 | 2020-2025 | Xtrac |
| Dermira, INC. | $248.31 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $232.99 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $231.36 | 2019-2020 | |
| Leo Pharma INC. | $223.95 | 2020-2025 | Adbry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $223.73 | 2019-2025 | Dupixent |
| Incyte Corporation | $210.54 | 2022-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $200.11 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $195.88 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.00 | 2023-2025 | Spevigo |
| Allergan, INC. | $123.49 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $115.06 | 2021 | |
| Galderma Laboratories, L.P. | $112.01 | 2019-2025 | Aklief |
| Janssen Scientific Affairs, LLC | $101.48 | 2019 | |
| Celgene Corporation | $88.28 | 2019 | |
| Almirall LLC | $60.83 | 2019-2021 | |
| Organon LLC | $57.12 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $55.18 | 2023-2024 | Sotyktu |
| Revance Therapeutics, INC. | $50.90 | 2024 | Daxxify |
| Krystal Biotech INC | $25.42 | 2023 | Vyjuvek |
| Dusa Pharmaceuticals, INC. | $17.71 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.40 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $13.20 | 2019 | |
| Prugen, INC. Pharmaceuticals | $2.19 | 2019 | |
| Journey Medical Corporation | $2.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.